// App-Quantinova.ai

: Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).

Researchers

Presenter

  • Eric Jay Small

Principal Investigators

  • Fred Saad

  • Simon Chowdhury

  • Stephane Oudard

  • Boris A. Hadaschik

  • Julie Nicole Graff

  • David Olmos

  • Paul N. Mainwaring

  • Ji Youl Lee

  • Hiroji Uemura

  • Angela Lopez-Gitlitz

  • Byron M. Espina

  • Youyi Shu

  • Wayne R. Rackoff

  • Oliver Brendan Rooney

  • Anil Londhe

  • Shinta Cheng

  • Matthew Raymond Smith

Medical Centers

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Georges Pompidou Hospital, Paris, France

  • University of Duisburg-Essen, Essen, Germany

  • Portland VA Health Care System and Knight Cancer Institute, Oregon Health & Science University, Portland, OR

  • Spanish National Cancer Research Centre (CNIO), Madrid and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga, Spain

  • Centre for Personalized Nanomedicine, University of Queensland, Brisbane, Australia

  • St. Mary's Hospital of Catholic University, Seoul, Korea, Republic of (South)

  • Yokohama City University Medical Center, Yokohama City, Japan

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, High Wycombe, United Kingdom

  • Janssen Research & Development, Yardley, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • United States

  • Canada

  • United Kingdom

  • France

  • Germany

  • Spain

  • Australia

  • Japan

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • NCT01946204

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved